Sepracor Inc.
Second study of eszopiclone in adults with chronic insomnia augment earlier findings
Published in Healthcare Finance, Tax and Law Weekly, November 2nd, 2005
The long-term, 828-patient, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of Lunesta also included a 2-week discontinuation phase in which all patients were administered placebo. This study is the second long-term, 6-month, double-blind, placebo-controlled study of Lunesta in patients suffering from chronic insomnia. The results of this study augment the findings of the first 6-month study, which was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Abaxis, Inc.
Lyophilization technology licensed to Cepheid - Acuity Medical
Electrical stimulation device treats age-related macular degeneration - Acusphere, Inc.
Microparticle drug technology developer closes common stock offering - Advance Nanotech, Inc.
Nanotechnology device funded to detect Avian influenza - Alexion Pharmaceuticals, Inc.
Heart disease drug maker reports loss of $1.16 per share - Arena Pharmaceuticals, Inc.
U.S. patent issued for 5-HT2C receptor modulators - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
